System, devices, and methods for real-time monitoring of cerebrospinal fluid for markers of progressive conditions

• US 20120238837A1
• Filed: 03/16/2011
• Published: 09/20/2012
• Est. Priority Date: 03/16/2011
• Status: Abandoned Application

• Current Assignee: Searete LLC (Intellectual Ventures LLC)
• Original Assignee: Searete LLC (Intellectual Ventures LLC)
• Inventors: Hyde, Roderick A., Wolda, Sharon L., Wood,, Lowell L. Jr.
• Application Number:
  US13/065,267
• Publication Number:
  US 20120238837A1
• Time in Patent Office: Days
• US Class Current: 600/310
• CPC Class Codes: A61B 5/14507 specially adapted for measuring characteristics of body fluids other than blood devices for taking samples of body liquids A61B10/0045
• CPC Class Codes: A61B 5/14546 for measuring analytes not otherwise provided for, e.g. ions, cytochromes
• CPC Class Codes: A61B 5/1459 invasive, e.g. introduced into the body by a catheter A61B5/1464 takes precedence
• CPC Class Codes: A61B 5/4058 for evaluating the central nervous system A61B5/4806, A61B5/4821 take precedence
• CPC Class Codes: A61B 5/686 Permanently implanted devices, e.g. pacemakers, other stimulators, biochips A61B5/6861 takes precedence
• CPC Class Codes: A61B 5/6868 Brain
• CPC Class Codes: A61M 27/006 Cerebrospinal drainage; Accessories therefor, e.g. valves

Abstract

Systems, devices, methods, and compositions are described for providing real-time monitoring of cerebrospinal fluid for markers of progressive conditions.

Claims

1. An indwelling implant, comprising:

a body structure having an inner surface defining one or more fluid-flow passageways configured to receive a cerebrospinal fluid;

a biomarker detection circuit configured to acquire at least one biomarker profile of a cerebrospinal fluid received within the one or more fluid-flow passageways; and

a mental disorder biomarker identification circuit configured to compare an acquired biomarker profile of the cerebrospinal fluid received within the one or more fluid-flow passageways to mental disorder filtering information.

10. The indwelling implant of claim 1, wherein the biomarker detection circuit includes a computing device configured to process sensor measurand information and configured to cause the storing of the measurand information in a data storage medium.

13. The indwelling implant of claim 1, wherein the biomarker detection circuit includes at least one computing device configured to determine a sampling regimen in response to sensor information.

26. The indwelling implant of claim 1, wherein the biomarker detection circuit includes at least one sensor component operably coupled to a psychotic disorder biomarker array.

27. The indwelling implant of claim 1, wherein the biomarker detection circuit includes at least one sensor component operably coupled to a neuropsychiatric disorder peptide biomarker array.

30. The indwelling implant of claim 1, wherein the biomarker detection circuit includes at least one computing device operably coupled to an array of sensors and configured to activate one or more of the sensors in the array of sensors in response to at least one of psychosis state information, psychosis trait information, psychosis prodromal information, or psychosis indication information.

33. The indwelling implant of claim 1, wherein the mental disorder biomarker identification circuit includes one or more data structures having mental disorder filtering information stored thereon, the mental disorder filtering information including user-specific mental disorder filtering information.

37. The indwelling implant of claim 1, wherein the mental disorder biomarker identification circuit includes one or more computer-readable memory media having mental disorder filtering information configured as a data structure, the mental disorder filtering information including at least one of upregulation model information associated with a VGF23-62 peptide, or decreased expression model information associated with a VGF26-62 peptide.

38. The indwelling implant of claim 1, wherein the mental disorder biomarker identification circuit includes one or more computer-readable memory media having mental disorder filtering information configured as a data structure, the mental disorder filtering information including at least one of user-specific upregulation model information associated with a VGF23-62 peptide, or user-specific decreased expression model information associated with a VGF26-62 peptide.

57. The indwelling implant of claim 1, further comprising:

a transcutaneous energy transfer system, the transcutaneous energy transfer system electromagnetically, magnetically, ultrasonically, optically, inductively, electrically, or capacitively-coupled to at least one of the biomarker detection circuit or the mental disorder biomarker identification circuit.

59. The indwelling implant of claim 1, wherein the mental disorder biomarker identification circuit includes one or more computing devices operable to compare a change associated with one or more biomarker levels of the cerebrospinal fluid received within the one or more fluid-flow passageways to the mental disorder filtering information.

78. The indwelling implant of claim 1, further comprising:

a communication circuit configured to transcutaneously communicate comparison information associated with comparing the detected at least one biomarker profile of the cerebrospinal fluid received within the one or more fluid-flow passageways to the mental disorder filtering information.

2-9. -9. (canceled)

11-12. -12. (canceled)

14-25. -25. (canceled)

28-29. -29. (canceled)

31-32. -32. (canceled)

34-36. -36. (canceled)

39-56. -56. (canceled)

58. (canceled)

60-77. -77. (canceled)

79. A system, comprising:

a progressive condition identification circuit configured to obtain in vivo cerebrospinal fluid information of a cerebrospinal fluid proximate a surface of an indwelling shunt; and

a decision signal circuit configured to signal a decision whether to transmit a notification in response to one or more comparisons between mental disorder filtering information specific to the biological subject and obtained in vivo cerebrospinal fluid information.

102. The system of claim 79, wherein the decision signal circuit includes one or more computer-readable memory media having reference cerebrospinal fluid information configured as a data structure.

105. The system of claim 102, wherein the data structure includes at least one of proteomic information indicative of a prodrome for a psychosis, peptidomic information indicative of a prodrome for a psychosis, or metabolic information indicative of a prodrome for a psychosis.

107. The system of claim 79, further comprising:

circuitry configured to generate a first response based at least in part on the one or more comparisons between the mental disorder filtering information specific to the biological subject and the obtained in vivo cerebrospinal fluid information of the biological subject.

108. The system of claim 79, further comprising:

circuitry configured to selectively tune a wavelength distribution of an interrogation electromagnetic energy.

109. The system of claim 79, further comprising:

circuitry configured to decide whether to report obtained in vivo cerebrospinal fluid information and when to report obtained in vivo cerebrospinal fluid information.

80-101. -101. (canceled)

103-104. -104. (canceled)

106. (canceled)

110-120. -120. (canceled)

121. A real-time monitoring method, comprising:

obtaining in vivo cerebrospinal fluid compositional information of a biological subject via an implanted sensor component; and

determining whether to transmit a notification in response to one or more comparisons between user-specific mental disorder filtering information related to the biological subject and obtained in vivo cerebrospinal fluid information of the biological subject.

125. The method of claim 121, wherein the obtaining the in vivo cerebrospinal fluid compositional information of the biological subject via the implanted sensor component includes detecting one or more spectral components indicative of a presence of at least one cerebrospinal fluid marker associated with a prodromal state of a psychotic disorder.

130. The method of claim 121, wherein the obtaining the in vivo cerebrospinal fluid compositional information of the biological subject via the implanted sensor component includes detecting one or more binding events indicative of a presence of at least one cerebrospinal fluid marker associated with a prodromal state of a psychotic disorder.

147. The method of claim 121, further comprising:

storing obtained in vivo cerebrospinal fluid compositional information in one or more memory structures.

150. The method of claim 121, further comprising:

providing time to onset information associated with a progressive condition based on the obtained in vivo cerebrospinal fluid compositional information.

152. The method of claim 121, further comprising:

updating the filtering information in response to one or more comparisons between filtering information specific to the biological subject and obtained in vivo cerebrospinal fluid information of the biological subject.

122-124. -124. (canceled)

126-129. -129. (canceled)

131-146. -146. (canceled)

148-149. -149. (canceled)

151. (canceled)

153-156. -156. (canceled)

157. An in vivo method for real-time monitoring of one or more biomarkers within cerebrospinal fluid, comprising:

comparing, using integrated circuitry, a detected compositional profile of a cerebrospinal fluid proximate a surface of an indwelling implant to neuropsychiatric disorder compositional information configured as a physical data structure; and

generating a response based on the comparing of the detected compositional profile to the neuropsychiatric disorder compositional information.

170. The in vivo method for real-time monitoring of biomarkers within cerebrospinal fluid of claim 157, wherein comparing, using integrated circuitry, the detected compositional profile of the cerebrospinal fluid proximate the surface of the indwelling implant to the neuropsychiatric disorder compositional information includes comparing the detected compositional profile to the neuropsychiatric disorder compositional information based on a transmitted request for a comparison.

181. The in vivo method for real-time monitoring of biomarkers within cerebrospinal fluid of claim 157, wherein generating the response includes generating an estimated time to occurrence information of a neurological pathology or a psychiatric pathology.

158-169. -169. (canceled)

171-180. -180. (canceled)

182-190. -190. (canceled)

191. An in vivo real-time monitoring method, comprising:

determining relative change information from a comparison between one or more compositional components of at least a second in time detected compositional profile of a cerebrospinal fluid proximate a surface of an indwelling implant and one or more compositional components of a first in time detected compositional profile of a cerebrospinal fluid proximate the surface of the indwelling implant; and

comparing the determined relative change information to reference neuropsychiatric disorder information stored in one or more non-transitory computer-readable memory media onboard the indwelling implant.

203. The in vivo real-time monitoring method of claim 191, wherein comparing the determined relative change information to the reference neuropsychiatric disorder information includes comparing the determined relative change information to cerebrospinal fluid biomarker spectral information associated with a schizophrenia prodrome.

192-202. -202. (canceled)

204-391. -391. (canceled)